Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial

Marcelo Augusto Duarte Silveira(D’Or Institute for Research and Education), Rogério da Hora Passos(Yahoo (Spain)), Thiago Cerqueira‐Silva(Universidade Federal da Bahia), Erica Batista dos Santos Galvão(D’Or Institute for Research and Education), Suzete Nascimento Farias da Guarda(Universidade Federal da Bahia), Raíssa Lanna Araújo San Martin(D’Or Institute for Research and Education), Márcio de Oliveira Silva(D’Or Institute for Research and Education), Silviana Salles Ultchak(D’Or Institute for Research and Education), Marcel Miranda Dantas Gomes(D’Or Institute for Research and Education), Andresa Aparecida Berretta(Universidade de São Paulo), Lucas Diniz da Conceição(D’Or Institute for Research and Education), Maurício Brito Teixeira(Universidade do Estado da Bahia), Thais Chaves Amorim(D’Or Institute for Research and Education), Fabio Santos Amorim(D’Or Institute for Research and Education), Lis Moreno(D’Or Institute for Research and Education), David De Jong(Universidade de Ribeirão Preto), Julio Cezar Miranda Sampaio(D’Or Institute for Research and Education), Sérgio Pinto de Souza(Escola Bahiana de Medicina e Saúde Pública), Paulo Benígno Pena Batista(D’Or Institute for Research and Education), Marcele Helena Celestino Alves dos Santos(D’Or Institute for Research and Education), Ana Verena Almeida Mendes(Escola Bahiana de Medicina e Saúde Pública), M. Isabel Vargas Lirio(D’Or Institute for Research and Education), Renata Mendonça(D’Or Institute for Research and Education), João Gabriel Rosa Ramos(D’Or Institute for Research and Education)
Biomedicine & Pharmacotherapy
March 20, 2021
10.1016/j.biopha.2021.111526
Cited by 121

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
|The Lancet|2020|5k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
|The Lancet|2021|1.2k
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
|The Lancet|2022|467
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil
|Emerging infectious diseases|2021|215
Low mortality rates related to respiratory virus infections after bone marrow transplantation
|Bone Marrow Transplantation|2003|104